Skip to content

Clinical trials

Phase 1 Head and Neck Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Head and Neck Neoplasms Phase: Phase 1 Country / region: United States Clear all

298 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20015
20023
20034
20047
200514
20069
200711
200811
200918
201011
201112
20129
20135
201415
201515
201613
20178
201813
201911
202015
202117
20229
202314
20248
202512
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed183
Terminated50
Recruiting25
Active, not recruiting19
Unknown status10
Withdrawn7
Suspended3
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)13
M.D. Anderson Cancer Center11
Memorial Sloan Kettering Cancer Center8
Dana-Farber Cancer Institute6
Pfizer6
Presage Biosciences6
University of Chicago6
Case Comprehensive Cancer Center4
Celldex Therapeutics4
Emory University4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Head and Neck Neoplasms298
Squamous Cell Carcinoma of Head and Neck86
Carcinoma, Non-Small-Cell Lung73
Colorectal Neoplasms65
Breast Neoplasms61
Ovarian Neoplasms58
Lung Neoplasms54
Melanoma49
Pancreatic Neoplasms49
Neoplasms42

Trials

Showing 1 to 25 of 298. Each trial links to its page on Pharma Observatory.

198 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.